OverviewDosage GuideSide EffectsProtocolResultsWeight LossClinical TrialsInjection GuideGLP-3How to GetCostFDA ApprovalAvailabilityTelehealthLiver FatMuscle LossWhere to Buy
BPC-157 Protocol Guide
A structured protocol for using BPC-157: cycle length, administration timing, stacking considerations, and monitoring.
Protocol Overview
Recommended Cycle Length
4–12 weeks (injury-dependent)
Dosing Frequency
Once or twice daily
Administration Route
Subcutaneous injection
Titration Required
Not typically required
Dosing Protocol
Starting dose: 200 mcg — Once or twice daily
Maintenance dose: 250-500 mcg — Once or twice daily
Most research protocols use 250–500mcg per injection, once or twice daily. Oral dosing also used for gut-specific effects (same dose range). Injectable BPC-157 should be reconstituted with bacteriostatic water.
Stacking & Combination Protocols
Important: Stacking BPC-157 with other active compounds significantly increases the complexity of managing side effects and monitoring. Always consult a qualified healthcare provider before combining compounds.
Commonly Discussed Combinations
TB-500 (Thymosin Beta-4)
Research only — animal evidence onlyThe most common BPC-157 stack. TB-500 promotes cell migration and new muscle fiber formation; BPC-157 drives angiogenesis and GH receptor upregulation. Together they address multiple healing pathways simultaneously.
Synergy: High synergy
NAD+ / NMN
Research onlyNAD+ precursors support cellular energy metabolism and mitochondrial function. When combined with BPC-157 during recovery, may provide enhanced cellular energy for tissue repair processes.
Synergy: Complementary
Vitamin C (high-dose)
Well-supported for collagen synthesisVitamin C is required for collagen synthesis — a key component of tendon and ligament repair. Supplementing during injury recovery (1–2g/day) may support the collagen-building processes that BPC-157 stimulates.
Synergy: Supporting
Do NOT Stack With
✗
Blood thinners / anticoagulants
BPC-157 promotes angiogenesis (new blood vessel formation). Combining with anticoagulants may increase bleeding risk.
✗
Use with active cancer history
BPC-157's angiogenic properties are a theoretical concern with existing tumors. Consult an oncologist before use.
✗
Unstable/acute inflammatory conditions
During acute severe inflammation, the pro-healing signaling of BPC-157 may have unpredictable effects.
Related Peptides
ipamorelin— commonly compared / discussed alongside BPC-157
Learn more →tirzepatide— commonly compared / discussed alongside BPC-157
Learn more →Monitoring While on Protocol
- ✓Track injury/pain scores weekly to assess healing progress
- ✓Note any unusual swelling, redness, or change at injection site
- ✓Document mobility improvements and range of motion changes
- ✓Check inflammatory markers (CRP) at baseline if monitoring systematically
- ✓Discontinue and consult provider if condition worsens
Exploring Retatrutide Access?
See how patients are accessing retatrutide through physician-supervised telehealth and compounding pharmacies.
Not FDA approved. Access requires physician oversight.
Affiliate links — we may earn a commission at no cost to you.
Medical Disclaimer: This protocol guide is for informational purposes only and is based on available research. It does not constitute medical advice. Work with a licensed healthcare provider to design and monitor your peptide protocol.